Well put Reyeton; enjoy your posts and share your sentiments. We should have much greater clarity over the coming 3-6 weeks as to the crucial efficacy question (for several indications).
IMO it’s time for a comprehensive reporting of NEW/RECENT/ROBUST DATA to investors and the scientific community.
If 11/4 doesn’t provide convincing and substantial data supporting dose dependent cognitive improvement/stabilization over 18/24 months along with further evidence/benefits of “restores cellular homeostasis”, then I will reassess this holding; however if they DO indeed illustrate same then all bets are off and patients/caregivers should rightfully be demanding fast access to this compound.
News 
Market Data 
Discover 
